# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001571049-17-007998
Filing Date
2017-09-22
Accepted
2017-09-22 08:30:29
Documents
5
Period of Report
2017-11-06
Effectiveness Date
2017-09-22

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFINITIVE PROXY STATEMENT | t1702290-def14a.htm | DEF 14A | 483164
2 | GRAPHIC | lg_phibrocorp-cmyk.jpg | GRAPHIC | 70242
3 | GRAPHIC | sg_thomas-dagger.jpg | GRAPHIC | 13593
4 | GRAPHIC | t1702290_pc1.jpg | GRAPHIC | 292544
5 | GRAPHIC | t1702290_pc2.jpg | GRAPHIC | 199891
| Complete submission text file | 0001571049-17-007998.txt |  | 1259891

Mailing Address GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666
Business Address GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666 201-329-7300
PHIBRO ANIMAL HEALTH CORP (Filer) CIK: 0001069899 (see all company filings)

EIN.: 131840497 | State of Incorp.: DE | Fiscal Year End: 0630
Type: DEF 14A | Act: 34 | File No.: 001-36410 | Film No.: 171096735
SIC: 2834 Pharmaceutical Preparations